2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.

Argenx reported positive Phase 2 results for FB102 in celiac disease, meeting its primary endpoint. The company will advance FB102 into Phase 3. Separately, argenx discontinued the Phase 3 UNITY study of efgartigimod in Sjögren's disease due to futility. Shares fell 7.91% overnight.

Argenx SE reported that its FB102 antibody met the primary endpoint in a Phase 2 celiac disease trial, showing statistically significant improvement over placebo. The company plans to advance the drug into Phase 3 development. Argenx's shares closed at US$928.44 on Wednesday, prior to the announcement. The trial measured intestinal damage, and the company noted a consistent safety profile. Argenx reported US$1.5 billion in Q2 product sales and US$472 million in profit.

argenx (ARGX) halted its Phase 3 UNITY trial for efgartigimod in Sjögren’s disease after the IDMC recommended stopping due to futility. The trial failed to meet its primary endpoint, though safety results aligned with expectations. The company will analyze data for future research. Efgartigimod is approved for other autoimmune diseases.

argenx reported positive Phase 2 results for FB102 in celiac disease, meeting the primary endpoint. The company plans to advance to Phase 3. According to the company, no new safety signals were observed.

argenx SE (ARGX) will halt its Phase 3 UNITY trial of efgartigimod SC in Sjögren's disease due to futility, following an IDMC recommendation. The company reports safety data were consistent with prior findings. This marks a setback in argenx's efforts to expand the drug's use in autoimmune diseases.

argenx reported positive Phase 2 results for FB102, a CD122 inhibitor, in celiac disease. The study met its primary endpoint (p=0.0176) and showed efficacy across multiple measures. The company plans to advance FB102 into Phase 3 development. FB102 is also being evaluated for other autoimmune diseases.